Edition:
United States

Juniper Pharmaceuticals Inc (JNP.OQ)

JNP.OQ on NASDAQ Stock Exchange Global Select Market

8.95USD
4:00pm EDT
Change (% chg)

$0.10 (+1.13%)
Prev Close
$8.85
Open
$9.05
Day's High
$9.05
Day's Low
$8.80
Volume
12,078
Avg. Vol
20,847
52-wk High
$13.10
52-wk Low
$4.05

Chart for

About

Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized... (more)

Overall

Beta: 0.53
Market Cap(Mil.): $98.24
Shares Outstanding(Mil.): 11.10
Dividend: --
Yield (%): --

Financials

  JNP.OQ Industry Sector
P/E (TTM): 4.26 28.62 32.94
EPS (TTM): 2.08 -- --
ROI: 45.59 13.26 12.79
ROE: 50.28 14.99 14.67

BRIEF-Juniper Pharmaceuticals Reports Q1 Earnings Per Share Of $0.06

* JUNIPER PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

May 10 2018

BRIEF-Daré Bioscience Enters Into Exclusive Worldwide License Agreement For Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform

* DARÉ BIOSCIENCE, INC. ENTERS INTO EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR JUNIPER PHARMACEUTICALS’ INTRAVAGINAL RING (IVR) TECHNOLOGY PLATFORM

Apr 25 2018

BRIEF-Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform To Daré Bioscience

* JUNIPER PHARMACEUTICALS LICENSES INTRAVAGINAL RING (IVR) PLATFORM TO DARÉ BIOSCIENCE

Apr 25 2018

BRIEF-Juniper Pharmaceuticals Appoints Richard Messina To Board Of Directors

* JUNIPER PHARMACEUTICALS APPOINTS RICHARD MESSINA TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 21 2018

BRIEF-Juniper Pharmaceuticals Qtrly Basic EPS $0.11

* JUNIPER PHARMACEUTICALS REPORTS FULL-YEAR 2017 FINANCIAL AND OPERATING RESULTS

Mar 08 2018

BRIEF-Juniper Pharmaceuticals To Explore Strategic Alternatives

* JUNIPER PHARMACEUTICALS - ‍ ENGAGED ROTHSCHILD AS ITS INDEPENDENT FINANCIAL ADVISOR TO ASSIST JUNIPER IN EVALUATING POTENTIAL STRATEGIC ALTERNATIVES​ Source text for Eikon: Further company coverage:

Jan 31 2018

BRIEF-Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress

* JUNIPER PHARMACEUTICALS OUTLINES STRATEGIC PRIORITIES FOR 2018 AND REPORTS RECENT PORTFOLIO PROGRESS

Jan 02 2018

Competitors

Earnings vs. Estimates